8-K: Alumis Reports Year-End 2024 Financial Results and Highlights Recent Achievements, Announces Merger Agreement with ACELYRIN

Alumis Inc. reported its year-end 2024 financial results, highlighted recent achievements, and announced a merger agreement with ACELYRIN to create a combined company with a strong late-stage portfolio.

Summary

• Alumis Inc., a clinical-stage biopharmaceutical company, announced its financial results for the year ended December 31, 2024.
• The company highlighted the presentation of Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025, demonstrating the efficacy and tolerability of ESK-001.
• Phase 3 ONWARD program data readout is now expected in Q1 2026.
• Alumis also presented Phase 1 clinical data at ACTRIMS 2025 for A-005, showing its ability to cross the blood-brain barrier.
• A Phase 2 trial of A-005 in multiple sclerosis is planned to begin in the second half of 2025.
• The company announced a merger agreement with ACELYRIN, expected to close in Q2 2025, creating a combined entity with a strong balance sheet and a differentiated late-stage portfolio.
• Alumis had cash, cash equivalents, and marketable securities of $288.3 million as of December 31, 2024.
• Research and development expenses were $265.6 million for the year ended December 31, 2024, compared to $137.7 million for the year ended December 31, 2023.
• Net loss for the year ended December 31, 2024, was $294.2 million, compared to $155.0 million for the year ended December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the merger announcement and progress in clinical trials, but tempered by the increased net loss and delayed Phase 3 data.

Positives

• ESK-001 demonstrated sustained clinical responses and a favorable safety profile in Phase 2 trials for psoriasis.
• A-005 showed the ability to cross the blood-brain barrier and was well-tolerated in Phase 1 trials.
• The merger with ACELYRIN is expected to create a leading immunology and inflammation company with multiple upcoming development milestones.
• The merger is expected to extend the company's cash runway into 2027.
• The company strengthened its leadership team with key appointments, including a new Chief Commercial Officer and Chief Legal Officer.

Negatives

• The company reported a significant net loss of $294.2 million for the year ended December 31, 2024, compared to $155.0 million in 2023.
• Research and development expenses increased substantially, impacting the bottom line.

Risks

• The merger with ACELYRIN is subject to stockholder approval and customary closing conditions.
• The Phase 3 ONWARD program data readout for ESK-001 in psoriasis has been delayed to Q1 2026.
• Clinical trials are subject to inherent risks, including the possibility of unfavorable results or delays.
• The company's success depends on the successful development and commercialization of its product candidates.

Future Outlook

Alumis anticipates major milestones in the next 12-18 months, including topline data from the pivotal Phase 3 program for ESK-001 in psoriasis expected in Q1 2026, initiation of a Phase 2 trial of A-005 in multiple sclerosis in 2H 2025, and data from ESK-001's Phase 2b clinical trial in systemic lupus erythematosus in 2026. The merger with ACELYRIN is expected to extend the company's cash runway into 2027.

Management Comments

• Alumis concluded a strong 2024, continuing to establish our late-stage pipeline of next-generation oral TYK2 inhibitors that have the potential to address significant unmet patient needs in immune-mediated diseases around the world, said Martin Babler, President and Chief Executive Officer of Alumis.
• The next 12-18 months will bring major milestones for Alumis, with topline data from the pivotal Phase 3 program for ESK-001 in moderate-to-severe plaque psoriasis expected in the first quarter of 2026.
• The announcement of the merger agreement with ACELYRIN represents a significant step forward in Alumis' strategic progress that will create a leading immunology and inflammation company with multiple upcoming expected development milestones and extend our runway into 2027, Babler added.

Industry Context

The announcement reflects a trend in the biopharmaceutical industry towards consolidation and strategic mergers to strengthen pipelines and extend financial resources. The focus on oral TYK2 inhibitors highlights the growing interest in targeted therapies for immune-mediated diseases.

Comparison to Industry Standards

• The development of ESK-001, a next-generation oral TYK2 inhibitor, positions Alumis in competition with companies like Bristol Myers Squibb (Deucravacitinib/Sotyktu) in the psoriasis market.
• The CNS-penetrant TYK2 inhibitor A-005 targets the multiple sclerosis market, where companies like Biogen, Novartis, and Roche have established therapies.
• The merger with ACELYRIN aims to create a combined entity competitive with other mid-sized biopharmaceutical companies focused on immunology and inflammation, such as UCB and Galapagos.

Management Changes

Stakeholder Impact

• Shareholders: The merger with ACELYRIN will result in a change in ownership structure, with Alumis stockholders owning approximately 55% of the combined company.
• Employees: The merger may lead to integration of teams and potential restructuring.
• Patients: Successful development of ESK-001 and A-005 could provide new treatment options for immune-mediated diseases.
• Suppliers and Partners: The merger may impact existing contractual relationships and collaborations.

Next Steps

• Closing of the merger transaction with ACELYRIN in Q2 2025.
• Initiation of Phase 2 clinical trial of A-005 in multiple sclerosis in 2H 2025.
• Finalizing the clinical development plan for Lonigutamab following the merger in mid-2025.
• Filing an Investigational New Drug Application for a third clinical candidate in 2025.
• Anticipating topline data from the Phase 3 ONWARD program for ESK-001 in psoriasis in Q1 2026.
• Anticipating topline data from the Phase 2b LUMUS clinical trial for ESK-001 in SLE in 2026.
• Anticipating topline data from the Phase 2 trial of A-005 in multiple sclerosis in 2026.

Key Dates

Keywords

Alumis, ACELYRIN, Merger, ESK-001, A-005, TYK2 inhibitor, Psoriasis, Multiple Sclerosis, Clinical Trials, Financial Results, Biopharmaceutical